Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is ...

A high-profile fight in the world of compounded drugs looks like it has been resolved, with telehealth firm Hims & Hers (HIMS ...

Novo's lawsuit comes less than one week after Hims & Hers announced plans to sell a compounded version of Novo's weight-loss ...

Hims & Hers said it would stop selling its new compounded semaglutide pill after "constructive conversations with ...

Semaglutide is the active ingredient in Ozempic and Wegovy. It’s a synthetic form of GLP-1, a hormone that regulates our ...

By Leah Douglas and Siddhi Mahatole Feb 6 (Reuters) - The U.S. Food and Drug Administration said on Friday it would take ...

The FDA has outlined numerous concerns about the sale and use of unapproved GLP-1 drugs for weight loss.  “FDA is aware that ...

FDA enforcement will focus on restricting GLP-1 APIs in mass-marketed, nonapproved compounded products to address unverifiable quality, safety, and efficacy under the FD&C Act. Appropriate compounding ...

With online health and wellness company Hims & Hers opening a new front in the GLP-1 compounding showdown Thursday, the ...

Legislative sessions are underway in most states, and some have introduced novel legislation to regulate compounded medications, including ...

On Feb. 6, 2026, FDA announced that it would take action to restrict access to GLP-1 ingredients for non-FDA approved compounded drugs. On the same day, the HHS General Counsel announced on social ...

Hims & Hers Health shares plunged Monday after the telehealth company said it would stop selling its compounded weight-loss ...